Clinical Trials · NCT02814097
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 46
- Start date
- Sep 2016
- Locations
- 9 sites, Germany, Serbia
- Primary endpoint
- Compare the delta in E/e' at rest exercise measured with echocardiography between the elamipretide and placebo groups